Synageva's LAL deficiency drug wins breakthrough designation from FDA

05/21/2013 | American City Business Journals

The FDA granted breakthrough therapy status to Synageva BioPharma's experimental drug sebelipase alfa, or SBC-102, as a treatment for early onset lysosomal acid lipase deficiency, also known as Wolman disease. The drug is currently in clinical trials against both early onset and late onset LAL deficiency. Sebelipase alfa previously won orphan designation and fast track status from the FDA.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA